WASHINGTON, DC -- August 6, 2010 -- New data released by the manufacturer of rasagiline (Azilect) confirms the drug's efficacy and safety for the treatment of patients with Parkinson's disease. "These results provide added support for a growing approach to treating patients with Parkinson's disease earlier in the course of their disease," said lead investigator Mark Lew, MD, University of Southern California, Los Angeles, California.
